Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of 250-mg ZD1839 Monotherapy in Recurrent or Metastatic or Both Recurrent and Metastatic Squamous Cell Carcinoma

NCT01185158 is registered in ClinicalTrials.gov with University of Chicago as lead sponsor.

NCT NCT01185158
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01185158 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of 250-mg ZD1839 Monotherapy in Recurrent or Metastatic or Both Recurrent and Metastatic Squamous Cell Carcinoma
Lead sponsor
University of Chicago
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2002
Completion date
November 30, 2010
Enrollment
46 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck cancer